menu
    • menu
    [{"orgOrder":0,"company":"Acrotech Biopharma","sponsor":"CASI Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Pralatrexate","moa":"Dihydrofolate reductase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Acrotech Biopharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Acrotech Biopharma \/ CASI Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Acrotech Biopharma \/ CASI Pharmaceuticals"},{"orgOrder":0,"company":"Acrotech Biopharma","sponsor":"Onxeo","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2020","type":"Agreement","leadProduct":"Belinostat","moa":"Histone deacetylase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Acrotech Biopharma","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Acrotech Biopharma \/ Acrotech Biopharma","highestDevelopmentStatusID":"15","companyTruncated":"Acrotech Biopharma \/ Acrotech Biopharma"},{"orgOrder":0,"company":"Acrotech Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Belinostat","moa":"Histone deacetylase","graph1":"Oncology","graph2":"Phase III","graph3":"Acrotech Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Acrotech Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Acrotech Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Acrotech Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Difamilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase III","graph3":"Acrotech Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Acrotech Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Acrotech Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Acrotech Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Difamilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Phase III","graph3":"Acrotech Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Acrotech Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Acrotech Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Acrotech Biopharma","sponsor":"Axis Clinicals Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Vincristine Sulfate","moa":"Tubulin","graph1":"Hematology","graph2":"Phase I","graph3":"Acrotech Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acrotech Biopharma \/ Axis Clinicals Ltd.","highestDevelopmentStatusID":"6","companyTruncated":"Acrotech Biopharma \/ Axis Clinicals Ltd."}]

    Find Clinical Drug Pipeline Developments & Deals by Acrotech Biopharma

    Menu

    Acrotech Biopharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Acrotech Biopharma

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            Acrotech Biopharma

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Belinostat

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            October 10, 2023

                            Lead Product(s) : Belinostat

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Acrotech Biopharma

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            Acrotech Biopharma

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pralatrexate

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : CASI Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Mundipharma International Corporation Limited, Mundipharma Medical Company, and Acrotech Biopharma Inc. Enter ...

                            Details : The partnership aims for the manufacturing and advancement of iTolerance's Streptavidin-FasL (SA-FasL) fusion protein, a crucial component of the proprietary iTOL-100 platform technology towards first in human clinical study for lead program, iTOL-102.

                            Product Name : Folotyn

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            January 08, 2023

                            Lead Product(s) : Pralatrexate

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : CASI Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Acrotech Biopharma

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            Acrotech Biopharma

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Difamilast

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            This Study is to Assess the Efficacy of Difamilast Ointment in Mild to Moderate Atopic Dermatitis(AD)

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 08, 2022

                            Lead Product(s) : Difamilast

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Acrotech Biopharma

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            Acrotech Biopharma

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Difamilast

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Open-label Study to Assess the Long-term Safety of Difamilast Ointment 1% in Mild to Moderate Atopic Dermati...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 07, 2022

                            Lead Product(s) : Difamilast

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Acrotech Biopharma

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            Acrotech Biopharma

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Belinostat

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Recipient : Onxeo

                            Deal Size : $6.6 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Onxeo to Receive $6.6 Million by Granting Additional Exclusive Rights to Belinostat to Acrotech Biopharma LLC

                            Details : The new Agreement grants Acrotech a royalty-free license to belinostat in all other territories including the United States, Canada, Mexico, and India.

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : $6.6 million

                            June 04, 2020

                            Lead Product(s) : Belinostat

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Recipient : Onxeo

                            Deal Size : $6.6 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Acrotech Biopharma

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            Acrotech Biopharma

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vincristine Sulfate

                            Therapeutic Area : Hematology

                            Study Phase : Phase I

                            Sponsor : Axis Clinicals Ltd.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            PK Study on Ready-to-Use Injection (VSLI-RTU) 1 Vial & 3 Vial Formulation Marqibo® in Hematological Maligna...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            January 28, 2020

                            Lead Product(s) : Vincristine Sulfate

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase I

                            Sponsor : Axis Clinicals Ltd.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Acrotech Biopharma

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            Acrotech Biopharma

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Belinostat

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Axis Clinicals Ltd.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Extension Study for Patients Who Had Not Met Criteria for Discontinuation in Previous Sponsored Belinostat Tri...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            December 04, 2019

                            Lead Product(s) : Belinostat

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Axis Clinicals Ltd.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Acrotech Biopharma

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            Acrotech Biopharma

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Belinostat

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Axis Clinicals Ltd.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Establish the PK of Belinostat in Patients With Wild-type, Heterozygous, and Homozygous UGT1A1*28 Genotypes

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            February 12, 2016

                            Lead Product(s) : Belinostat

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Axis Clinicals Ltd.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Acrotech Biopharma

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            Acrotech Biopharma

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Belinostat

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Axis Clinicals Ltd.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            To Evaluate Safety and Pharmacokinetics of Belinostat in Patients Who Have Mild, Moderate and Severe Renal Imp...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            February 10, 2016

                            Lead Product(s) : Belinostat

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Axis Clinicals Ltd.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Acrotech Biopharma

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            Acrotech Biopharma

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pralatrexate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Axis Clinicals Ltd.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus CHOP With Peripheral T-Cell Lymphoma (PTCL)

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 03, 2015

                            Lead Product(s) : Pralatrexate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Axis Clinicals Ltd.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth